Prostate Cancer Clinical Trials in Boston

Showing 121-140 of 221 trials

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

NCT03602079

Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Patients will receive study drug as a single IV infusion. Cycles will continue until disease progression or unacceptable toxicity.

HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more

Klus Pharma Inc.49 participantsStarted Jul 2018

Sarasota, Florida, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +7 more locations

WITHDRAWNPhase 2< 1 mile

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04781374

This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. \- The names of the study drug involved in this study is neratinib.

Metastatic Prostate AdenocarcinomaCastration-resistant Prostate CancerProstate Cancer+1 more

Beth Israel Deaconess Medical CenterStarted May 2021

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Trials in Other Cities

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

The Genomic Medicine at VA Study

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Radiation Therapy in Treating Patients With Prostate Cancer

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Safety Study of MGA271 in Refractory Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

Cabazitaxel and Radiation For Patients With Prostate Cancer

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Other Conditions in Boston